Work

LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.4546

Authors: Eric Jonasch, Othon Iliopoulos, Wendy Kimryn Rathmell, Vivek Narayan, Benjamin L. Maughan, Stephane Oudard, Tobias Else, Jodi K. Maranchie, Sarah Joanne Welsh, Ane Bundsbæk Bøndergaard Iversen, Ananya Roy, Yanfang Liu, Rodolfo F. Perini, W. Marston Linehan, Ramaprasad Srinivasan

Institutions: The University of Texas MD Anderson Cancer Center, Harvard University, Massachusetts General Hospital, Vanderbilt University Medical Center, University of Pennsylvania, University of Utah, Université Paris Cité, University of Michigan, University of Pittsburgh, Cambridge University Hospitals NHS Foundation Trust, Aarhus University Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), National Cancer Institute, Center for Cancer Research

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286295708

Cites:

Cited by: 21

Related to: 10